Ankylosing Spondylitis is a type of arthritis that primarily affects the spine and pelvis.
Mannose–binding lectin (MBL) deficiency and tuberculosis infection in patients with ankylosing spondylitis (AS). We found a significant association between MBL deficiency and higher risk of tuberculosis and urinary tract infection in patients with AS. PubMed, Clin Rheumatol, 09/06/2017. (Also see Extrapulmonary Tuberculosis)
Effectiveness of exercise programs in ankylosing spondylitis (AS): A meta–analysis of randomized controlled trials. Despite the small number of patients and the heterogeneity of exercise programs in this meta–analysis, its results support the potential of exercise programs to improve disease activity and body function in AS. PubMed, Arch Phys Med Rehabil, 08/28/2017.
Prevalence of cardiovascular–related (CVD) comorbidity in ankylosing spondylitis (AS), psoriatic arthritis (PsA) and psoriasis (Ps) in primary care: a matched retrospective cohort study. Our findings provide UK comparisons of CVD–related comorbidities in patients with AS, PsA and Ps alone, which further supports the argument for more evidence in the need for screening and intervention around CVD comorbidities in inflammatory conditions. PubMed, Clin Rheumatol, 08/02/2016. (Also see Psoriasis and Psoriatic Arthritis)
Effect of secukinumab on patient–reported outcomes in patients with active ankylosing spondylitis: A Phase 3 randomized trial (MEASURE 1). Secukinumab provided significant and sustained improvements in health–elated quality of life, and reduced functional impairment, fatigue, and impact of disease on work productivity in patients with active AS. PubMed, Arthritis Rheumatol, 07//07/2016.
Spinal fractures in patients with ankylosing spondylitis. The aim of this review article was to provide the required clinical knowledge that radiologists need to know and the relevant radiological semiotics that clinicians require in diagnosing clinically significant injury to the ankylosed spine. PubMed, Rheumatol Int, 07/05/2016.
The effectiveness of a real life dose reduction strategy for TNF inhibitors in ankylosing spondylitis (AS) and psoriatic arthritis (PsA). In a real–world setting, 60% of individuals with severe AS and PsA who achieve low disease activity can successfully reduce the dose of TNF inhibitor therapy by a third for a mean of 1 year. PubMed, Rheumatology (Oxford), 06/28/2016. (Also see Psoriasis and Psoriatic Arthritis)
Vitamin D, disease activity and comorbidities in early spondyloarthritis. In early axial spondyloarthritis vitamin D deficiency was associated with higher disease activity and severity and presence of metabolic syndrome. PubMed, Clin Exp Rheumatol, 04/05/2016. (Also see Vitamin D)
Effectiveness of ultrasound treatment applied with exercise therapy on patients with ankylosing spondylitis: a double–blind, randomized, placebo–controlled trial. The study showed that ultrasound treatment increases the effect of exercise in patients with ankylosing spondylitis. PubMed, Rheumatol Int, 02/29/2016.
The role of biomechanical factors in ankylosing spondylitis (AS): the patient’s perspective. Patients report physical trauma, exercise and physiotherapy as potential triggers for AS symptoms and these findings further support the experimental evidence for the role of biomechanical factors in disease. Rheumatismo, 02/11/2016.
Occasional presence of herpes viruses in synovial fluid and blood from patients with rheumatoid arthritis and axial spondyloarthritis. Results indicate the occasional presence of DNA from herpes viruses in patients with rheumatoid arthritis or with axial spondyloarthritis. PubMed, Clinical Rheumatology, 05/20/2015. (Also see Symptoms and Complications of Rheumatoid Arthritis)
Aortic regurgitation is common in ankylosing spondylitis - time for routine echocardiography evaluation? As aortic regurgitation and/ or conduction abnormalities might cause insidious symptoms, both electrocardiography and echocardiography evaluation should be part of the routine management of patients with ankylosing spondylitis. PubMed, Am J Med, 06/04/2015. (Also see Diagnosis of Heart Involvement)
Referral patterns, diagnosis, and disease management of patients with axial spondyloarthritis (SpA): results of an international survey. Referral patterns, diagnosis, and disease management for axial SpA were similar among rheumatologists and disease-modifying antirheumatic drugs were commonly prescribed for axial SpA patients. PubMed, J Clin Rheumatol, 2014 Dec;20(8):411-7. (Also see DMARDs)
The use of anti-TNF therapy for ankylosing spondylitis in everyday rheumatology practice and the relationship to disease activity, work disability and diagnostic delay. Despite the appropriate use of anti-TNF agents, we continue to see high rates of unemployment in this patient group which can impact both on the person and society and bears further consideration. PubMed, Ir J Med Sci, 2014 Dec;183(4):579-84.
Infliximab has no apparent effect in the inner ear hearing function of patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Our study showed that there was no notable change or deterioration in the hearing function of the patients with AS and RA who were treated with infliximab. PubMed, Clin Rheumatol, 2014 Oct;33(10):1481-7. (Also see Rheumatoid Arthritis Treatments)
(Case Report) Coexistence of Ankylosing Spondylitis (AS) With Morphea. Morphea and AS with an inflammatory background and active immunity can exist in the same patient and recent studies have showed the importance of Th17 and associated cytokines in the pathogenesis of these two diseases. Archives of Rheumatology, 2014, Volume 29, Number 2, P 143-146. (Also see Morphea and Causes of Scleroderma: Cytokines)
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Juliet Youkhana; and donations in loving memory of Jim Miller and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE sclero.org button.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: